Abstract 56P
Background
The incidence of colorectal cancer (CRC) has increased among the younger population. Adolescents and young adults (AYA) are an important component of the active population in any country that impact the health care system along with socio-economic consequences. We present one of the first multicentre collaborative studies on AYA CRC from a low and middle-income country (LMIC).
Methods
The study was a multicentre retrospective registry conducted over the period of 3 years, from January 2018 to December 2020, after approval from respective IECs. A total of 126 AYA CRC Patients were enrolled in the study. The details regarding socio-demographic profile, histopathology, and therapeutic details were recorded.
Results
A total of 126 patients of AYA colorectal cancer patients were enrolled in the study between 2018 - 2020. 62.70% of patients had colon cancer, 37.30 % had rectal cancer. 50.79 % of patients were male. 67.46% of patients belong to 31-40 age group, with an average age of 32.6 years. Abdomen pain and distension (34%), and blood in stools (22%) were the most common presentations. On presentation, 31.75% had cTNM stage IV, 28.57% stage III, 15.87% stage II as per AJCC 8. 92(74.60%) underwent surgery, and adenocarcinoma (65.08 %) was the most common histology. 28.57% of patients were stage III on pTNM. Most of the patients were offered potentially curative therapy (65.87%), and 33.33% of patients were on palliative treatment. CAPOX was the most commonly prescribed chemotherapy regimen. MSI profiling was available only for eight patients.
Conclusions
As per our knowledge, this study is one of the first multicentre collaborative studies from an LMIC related to the clinic-pathological profile of AYA CRC patients. Most such patients present in non-metastatic stage, and potentially receive curative therapy. However, only a small minority could get MSI/mutational profiling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Biotechnology Industry Research Assistance Council (BIRAC) India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Long-term clinical outcomes after the second metastasectomy in patients (pts) with resected metastatic colorectal cancer (mCRC)
Presenter: Songji Choi
Session: Poster viewing 02
49P - Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study
Presenter: Thorsten Goetze
Session: Poster viewing 02
50P - Linear tumor regression of rectal cancer in daily MRI during preoperative chemoradiotherapy: An insight of tumor regression velocity for personalized cancer therapy
Presenter: Sea-Won Lee
Session: Poster viewing 02
51P - Efficacy and safety of sintilimab as first-line therapy in patients with microsatellite instability-high metastatic colorectal cancer: A real-world study
Presenter: Caiyun Nie
Session: Poster viewing 02
53P - Baseline PET/CT deep radiomics signature apply for identifying bevacizumab sensitivity of RAS-mutant colorectal cancer liver metastases patients
Presenter: Wenju Chang
Session: Poster viewing 02
54P - Efficacy of total neoadjuvant therapy (TNT) in rectal cancer: A meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: Poster viewing 02
55P - Biodegradable and biocompatible 3D-printed scaffolds loaded with chemotherapy drugs: A new horizon for treatment of colon cancer with diffuse intraperitoneal metastasis
Presenter: Amirhosein Kefayat
Session: Poster viewing 02
57P - V-set and immunoglobulin domain containing 1 (VSIG1): Gene vs protein expression in colorectal cancer tissue samples
Presenter: Simona Gurzu
Session: Poster viewing 02